Table 1.
Baseline characteristics and 18F-DCFPyL dosing/uptake time
| Characteristics | n = 208 |
|---|---|
| Age (years): median (range) | 68 (43, 91) |
| Age ≥65 years, n (%) | 141 (67.8) |
| Months from prostate cancer diagnosis: median (range) | 71 (3, 356) |
| Prior prostate cancer therapies | |
| RP only, n (%) | 103 (49.5) |
| RT only, n (%) | 31 (14.9) |
| RP and RT, n (%) | 74 (35.6) |
| At least 1 prior systemic therapy, n (%) | 58 (27.9) |
| Total Gleason Score, n (%) | |
| < 8 | 153 (73.6) |
| < 6 | 3 (1.4) |
| 3 + 3 = 6 | 12 (5.8) |
| 3 + 4 = 7 | 78 (37.5) |
| 4 + 3 = 7 | 60 (28.8) |
| ≥ 8 | 55 (26.4) |
| 3 + 5 = 8 | 0 |
| 4 + 4 = 8 | 21 (10.1) |
| 5 + 3 = 8 | 0 |
| 4 + 5 = 9 | 31 (14.9) |
| 5 + 4 = 9 | 3 (1.4) |
| 5 + 5 = 10 | 0 |
| PSA (ng/mL) (n=202): Median (range) | 0.8 (0.17, 98.45) |
| PSA sample collection study day prior to administration of 18F-DCFPyl (Study Day) (n=202): Median (range) | 1 (−29, 1) |
| PSA Group (n=202), n (%) | |
| <2.0 ng/mL | 139 (68.8) |
| <0.5 ng/mL | 69 (34.2) |
| 0.5 to <1.0 ng/mL | 37 (18.3) |
| 1.0 to <2.0 ng/mL | 33 (16.3) |
| ≥2.0 ng/mL | 63 (31.2) |
| 2.0 to <5.0 ng/mL | 33 (16.3) |
| ≥5.0 ng/mL | 30 (14.9) |
| 18 F-DCFPyL dosing and uptake time | |
| Administered activity (mCi/MBq): median (range) | 9.42 (7.49–11.07)/349 (277–410) |
| Time from injection to imaging (minutes): median (range) | 79 (59–115) |
Abbreviations: PSA: Prostate-specific antigen; RP: Radical prostatectomy; RT: Radiation therapy